The First Affiliated Hospital of Nanchang University
Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751966
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752057
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751901
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional second-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751940
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06752044
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
- Conditions
- Advanced NSCLC
- Interventions
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751849
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional second-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751914
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Combination Product: Conventional third-line therapy
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 10
- Registration Number
- NCT06751953
- Locations
- 🇨🇳
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Hospital of Nanchang, Nanchang, Jiangxi, China
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
- Conditions
- Acute Pancreatitis
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-06
- Target Recruit Count
- 60
- Registration Number
- NCT06639516
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
- Conditions
- Acute Pancreatitis
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Target Recruit Count
- 176
- Registration Number
- NCT06230432
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China